Rapport Therapeutics (RAPP) CDO Krishnaswamy Sells 360 Shares

What Happened Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 360 shares in an open-market/private sale on April 8, 2026. The shares traded at $34.90 apiece for a total value of $12,564. This was a sale (not a purchase); sales by insiders can be routine and do not necessarily indicate a change in view on the company.

Key Details

• Transaction date and price: April 8, 2026 — 360 shares sold at $34.90 per share (total $12,564).
• Filing date: Form 4 filed April 9, 2026 for the April 8 transaction (filed the next business day).
• Shares owned after transaction: Not specified in the provided summary of the filing (see the SEC filing for the exact post-transaction beneficial ownership).
• Footnote: The sale was effected under a pre-established Rule 10b5-1 trading plan adopted December 10, 2025 (F1).
• Transaction code: S = Sale.

Context Transactions executed under 10b5-1 plans are pre-scheduled and commonly used by insiders to avoid trading based on nonpublic information; they are generally viewed as routine. The size of this sale (~$12.6k) is modest for an executive and, by itself, is not a strong signal of management sentiment. For full details (exact post-transaction holdings, plan terms), consult the complete SEC Form 4 (Accession No. 0001193125-26-149725).